NeoGenomics’ $171 Million Common Stock Offering


Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the follow-on offering of 8,050,000 shares of common stock of NeoGenomics, Inc. for total gross proceeds of approximately $171 million.

Morgan Stanley & Co. LLC, SVB Leerink LLC and William Blair & Company, L.L.C. acted as joint book-running managers and representatives of the several underwriters in the deal.

The common stock is listed on the Nasdaq Global Select Market under the symbol “NEO.”

NeoGenomics specializes in cancer genetics testing and information services. NeoGenomics provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. NeoGenomics’ Pharma Services division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks and managed care organizations throughout the United States.

The Davis Polk corporate team included partner Alan F. Denenberg (Picture) and associate Jacqueline Marino. The intellectual property and technology team included partner Frank J. Azzopardi and associates Christopher C. Woller and Yifu Chen. Partner Michael Farber and associate Yixuan Long provided tax advice.

Involved fees earner: Frank Azzopardi – Davis Polk & Wardwell; Yifu Chen – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Yixuan Long – Davis Polk & Wardwell; Jacqueline Marino – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Morgan Stanley; SVB Leerink LLC; William Blair & Company, L.L.C.;

Author: Ambrogio Visconti